When: March 10, 2008

Where: Stevenage, United Kingdom

Stevenage, United Kingdom, March 10th, 2008: Skura, the leader in next generation software solutions for Closed-Loop Marketing (CLM) in the Life Sciences industry is proud to announce an agreement with Novartis Pharma Germany to provide the Skura SFX™ Suite as the preferred solution for their CLM initiative.

Novartis Pharma Germany is exploring new technologies and concepts that would enhance the effectiveness of their sales and marketing campaigns. Skura is very pleased to have been chosen based on the evaluation of several criteria and is looking forward to the opportunity to partner with Novartis Pharma Germany to make this initiative a success. The pilot phase of the project is currently underway.

The Skura SFX Suite is the most advanced sales/marketing Tablet PC detailing software available. It enables Pharmaceutical and Life Sciences companies to detail the right physician, using the right multimedia message, at the right time.

About Skura

Founded in 1996, Skura has grown into an international company with satisfied customers in 22 countries. Life Science manufacturers have benefited from Skura's unique value proposition as a provider of full CRM consulting services and market leading innovative software solutions for Closed-Loop Marketing (CLM) and Tablet PC detailing.

Skura Corporation is recognized for its expertise in helping Life Science customers maximize their investments in Customer Relationship Management (CRM) technology by enhancing the investments already made. Using best-in-class applications from Oracle, Siebel, Siperian, Microsoft, and our own products, Skura has been delivering quality solutions that increase sales, marketing, and medical effectiveness and efficiency for over a decade.

As a recognized leader of software solutions and services, Skura continues to earn an envied reputation in process design, as well as technical development and support of Oracle technologies.

For more information on Skura Corporation and CLM solutions, please visit www.skura.com.

About Novartis

Novartis AG provides healthcare solutions that address the evolving needs of patients and societies. Focused solely on growth areas in healthcare, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, and consumer health products. Novartis is the only company with leading positions in these areas. In 2007, the Group's continuing operations (excluding divestments in 2007) achieved net sales of USD 38.1 billion and net income of USD 6.5 billion. Approximately USD 6.4 billion was invested in R&D activities throughout the Group. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 98,200 full-time associates and operate in over 140 countries around the world. For more information, please visit www.novartis.com.

For more information contact:

Jim Sale
Managing Director
Skura Europe Ltd.
jsale@skura.com